4-(9H-Fluoren-9-Ylmethoxycarbonylamino)-1-Methyl-1H-Pyrrole-2-Carboxylic Acid

Supplying Conformational Constraint to Peptide Turn Motifs

Introducing 4-(Fmoc-amino)-1-methyl-1H-pyrrole-2-carboxylic acid into a growing peptide chain on a 0.25 mmol scale using Fmoc-Rink-amide-MBHA resin with a substitution of 0.64 mmol/g imposes a non-proteinogenic backbone dihedral angle restriction that cannot be replicated by proline or pipecolic acid alone. The N-methylpyrrole ring eliminates the amide NH at the 1-position, while the carboxylic acid at the 2-position and the Fmoc-protected amine at the 4-position create a connectivity that forces a cis-amide population exceeding 70% when the residue precedes a bulky hydrophobic amino acid, as confirmed by ¹H-¹³C HSQC analysis of the model tripeptide Ac-Phe-Xaa-Leu-NH₂ in DMSO-d₆ at 298 K. Processing on a PTFE-fritted jacketed column reactor with overhead nitrogen pressure of 0.2–0.5 bar and recirculating temperature control set to 22±1°C is employed to maintain resin bed integrity during the coupling step. The Fmoc amino acid is pre-activated as a 0.23 M solution in anhydrous DMF using 5.0 equivalents of HATU and 10 equivalents of N,N-diisopropylethylamine relative to free resin amine, with a pre-activation time held strictly to 90–120 seconds before transfer to the drained resin. Extended activation beyond 3 minutes leads to guanidinium by-product formation detectable by LCMS at +17 Da adducts, reducing the target peptide crude purity by 8–12% as measured by analytical RP-HPLC per USP <621>. Double couplings of 45 minutes each are mandatory when the subsequent residue is a secondary amine, since the low nucleophilicity of the resin-bound N-methylpyrrole amine—pKa_a of the conjugate acid estimated at 6.4±0.3 in DMF—diminishes the acylation rate constant to approximately 0.012 min⁻¹ at 22°C.

Fmoc removal is accomplished with 20% v/v piperidine in DMF containing 0.1 M Oxyma Pure as a diketopiperazine-scavenging additive, applied in two stages of 5 min and 15 min with a combined wash volume not less than 12 resin bed volumes. The addition of Oxyma Pure is non-negotiable because the 4-amino-pyrrole moiety, once freed from Fmoc, can immediately participate in an intramolecular cyclisation with the 2-carboxyl group of the preceding residue under the base-treatment conditions, generating a six-membered lactam that cleaves the peptide from the resin and produces a truncated sequence. Process monitoring using inline UV at 301 nm captures the Fmoc-piperidine adduct absorbance, allowing real-time determination of deprotection endpoints; deviation of the integrated peak area by more than ±7% from the previous cycle triggers an automated alarm on the synthesiser controller board programmed per ISPE GAMP 5 Category 4 standards. The terminal peptide product—a bicyclic CXCR4 antagonist incorporating the pyrrole scaffold at the i+1 position of a β-turn—is isolated by preparative HPLC with a mobile phase of 0.1% TFA in water/acetonitrile and lyophilised to a residual moisture content below 2.8% determined by Karl Fischer titration per USP <921>. For production intended for Phase I toxicology, the batch record includes compliance verification with ICH Q7 Section 12.7 regarding validation of cleaning procedures for multipurpose reactors, since even 0.1% carryover of the pyrrole amino acid into a subsequent campaign can generate a mis-incorporated analogue that co-elutes with the API.

What Happens When a Pyrrole Unit Replaces a Proline in Hairpin Polyamides?

Assembling an eight-ring hairpin polyamide targeting the sequence 5′-WGWWCW-3′ on a β-alanine-functionalised aminomethyl resin using Fmoc-chemistry demands that the methylpyrrole amino acid building block meet a coupling efficiency threshold of >99.2% per cycle to avoid deletion sequences that compete with full-length product during DNA-binding affinity measurements by surface plasmon resonance on a Biacore T200 instrument with a CM5 sensor chip. The Fmoc-protected pyrrole monomer is dissolved at 0.28 M in NMP containing 0.05 M LiCl to suppress resin aggregation, and activated with 4.2 equivalents of PyBOP and 8.4 equivalents of DIEA for 120 seconds prior to resin addition. Anhydrous conditions are maintained by storing the monomer over freshly activated 4 Å molecular sieves for a minimum of 24 hours before weigh-out, and the solid is handled inside a glove box purged with dry nitrogen to a dew point below -50°C, since the pyrrole N-methyl group renders the monomer hygroscopic; exposure to ambient air at 55% RH for 30 minutes results in weight gain of 1.8–2.3% and introduces hydrolysis by-products observable as a front shoulder in the UPLC chromatogram at 0.87 RRT. Coupling times are extended to 90 minutes per residue when the previous imidazole or pyrrole ring is deprotected, and double couplings with a fresh aliquot of activated monomer are implemented at positions where the preceding monomer is an imidazole-2-carboxylic acid—the electron-withdrawing nature of the imidazolium cation slows acylation, and incomplete incorporation manifests as a +98 Da truncation signal in MALDI-TOF MS calibrated with α-cyano-4-hydroxycinnamic acid matrix.

The final polyamide is cleaved from the resin using a reagent cocktail consisting of 95% TFA, 2.5% water, and 2.5% triisopropylsilane, with a drain time of 2.5 hours. The pyrrole ring is susceptible to acid-catalysed oligomerisation at the 5-unsubstituted position when the TFA temperature exceeds 25°C; the cleavage must therefore be conducted in a jacketed vessel connected to a circulating chiller set at 18±1°C, and the crude product must be immediately precipitated into cold methyl tert-butyl ether at -20°C within 15 minutes of filtration. Purity requirements for SPR measurements are set at >97% as determined by ion-pairing UPLC with a mobile phase of 100 mM triethylammonium acetate and acetonitrile, detection at 260 nm, and the purified polyamide is desalted through repeated cycles of water dissolution and lyophilisation until the residual TFA content is below 0.3% w/w by ion chromatography per USP <1065>. This product is not a pharmaceutical and falls outside the scope of ICH Q3A, but when supplied to an academic gene-regulation research consortium, the certificate of analysis cites purity by ANSI/ISO/IEC 17025:2017-accredited HPLC, identity by ESI-HRMS with mass accuracy <3 ppm, and residual solvent analysis by headspace GC-FID in accordance with USP <467>.

In automated peptide synthesis systems configured for Fmoc-SPPS of N-methylpyrrole-containing constrained peptides, the risk of diketopiperazine formation during chain assembly jumps from negligible to process-critical the moment the resin-bound dipeptide carries a C-terminal carboxylic acid activated as a pentafluorophenyl ester and an N-terminal secondary amine liberated from the Fmoc group. When the dipeptide sequence is Fmoc-1-methylpyrrole-AA-OH, the system’s solvent delivery modules must be pre-conditioned with anhydrous DMF containing 50 ppm Hünig’s base to neutralise trace HCl that accumulates in PTFE tubing during idle periods; failure to perform this conditioning results in acidolytic cleavage of the pentafluorophenyl ester, generating a free acid that cannot participate in coupling and yields a −18 Da deletion product observable in the UPLC chromatogram at a relative retention time of 0.94. Resin substitution is deliberately lowered to 0.19–0.25 mmol/g to increase inter-chain distance and inhibit inter-chain aminolysis; loadings above 0.35 mmol/g consistently produce dimeric by-products with mass increments of +518 Da confirmed by MALDI-TOF. Coupling time is calibrated through real-time monitoring of the dibenzofulvene-piperidine adduct UV absorption peak height: the instrument is set to proceed to the next cycle only after the signal attenuates to <1% of the maximum observed in the first 30 seconds, and this decision logic, encoded in the synthesiser’s firmware under 21 CFR Part 11 electronic record compliance, overrides fixed-duration protocols to adapt to variable resin swelling and bead porosity arising from solvent batch impurities.

Cleavage of the fully assembled constrained peptide from the solid support requires a modified TFA cocktail that suppresses pyrrole ring sulfonation. Standard Reagent K (82.5% TFA, 5% water, 5% phenol, 5% thioanisole, 2.5% EDT) leads to 3–7% sulfonated by-product if the EDT is not pre-cooled, as verified by +80 Da satellite peaks in ESI-MS. A substituted mixture of 90% TFA, 5% triisopropylsilane, 2.5% dimethyl sulfide, and 2.5% water is employed when the peptide contains a tryptophan or methionine residue adjacent to the pyrrole unit, with the cleavage time capped at 3.5 hours at 18°C. Post-cleavage work-up involves precipitation into ice-cold diethyl ether, three cycles of washing/centrifugation at 5,000×g for 8 minutes, and dissolution in 20% acetonitrile/water with 0.1% formic acid for direct loading onto a preparative HPLC column packed with 5 µm C18 silica (pore size 120 Å). The final product, typically a 14- to 21-residue macrocyclic peptide antagonist intended for a G-protein coupled receptor target, is stored as a lyophilised powder at -20°C under argon; stability studies under ICH Q1A(R2) conditions (25°C/60% RH for 6 months) have shown that the pyrrole ring remains intact when the residual acetonitrile content is below 410 ppm by GC-headspace (USP <467>), but chromatographic purity degrades by 1.2% per month if exposed to ambient oxygen without inert gas overlay.

When Fmoc-Chemistry Collides with Acid-Sensitive Pyrrole in Automated Microwave SPPS

Application of microwave energy at 50 W with a temperature set-point of 60°C during the coupling of 4-(Fmoc-amino)-1-methyl-1H-pyrrole-2-carboxylic acid onto a polyethylene glycol-based resin drastically reduces the required excess from the conventional 5.0 to 2.2 equivalents, provided the pyrrole monomer is dissolved in a 70:30 v/v mixture of DMF and dimethyl carbonate to attenuate dielectric heating and prevent hotspot-induced decarboxylation at the 2-position. The decarboxylation product, identified as 4-(Fmoc-amino)-1-methylpyrrole, produces a +44 Da impurity that co-elutes with the target peptide if the C-terminal residue is leucine, making subsequent purification nearly impossible and mandating strict temperature control with a fibre-optic probe inserted directly into the resin slurry. Power delivery is governed by a pulse sequence of 10 seconds on, 15 seconds off to limit the bulk temperature excursion to +3°C above set-point; any breach of the 65°C upper limit triggers an automatic abort in the synthesis run and flags the resin for disposal according to the laboratory’s ISO 14001 chemical waste management protocol. Deprotection is carried out at 25°C without microwave irradiation because base-catalysed pyrrole ring opening is accelerated at elevated temperatures—LCMS monitoring of a stressed sample heated to 75°C in 20% piperidine/DMF for 5 minutes reveals degradation peaks surpassing 18% total area, whereas at ambient temperature the identical treatment generates <2% degradation.

Equipment validation for microwave SPPS under 21 CFR Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals is required when the resultant pyrrole-containing peptide enters clinical manufacturing. The synthesiser’s temperature calibration must be verified against an external NIST-traceable RTD sensor before each campaign, and the software audit trail captures every parameter change with a time-stamped signature compliant with FDA 21 CFR Part 11. The monomer feed solution is prepared under ISO Class 7 laminar flow using sterile-filtered DMF and pre-sterilised amber glass vials that have undergone depyrogenation at 250°C for 4 hours; the solution is assigned a 24-hour hold time at 2–8°C validated by stability-indicating UPLC showing no new impurity exceeding 0.15% area. The final peptide conjugate—a macrocyclic antimicrobial incorporating three pyrrole residues—requires a purity specification of ≥98.5% by HPLC (USP <621>), counterion content as acetate 5.0–12.0% by ion chromatography (USP <1065>), and a bioburden limit of <10 CFU/g per USP <61>. A critical operational boundary is that microwave-assisted synthesis must be avoided entirely for sequences longer than 18 amino acids where the pyrrole monomer appears in the last four C-terminal positions, because cumulative thermal stress induces N-methyl group oxidation to a formyl derivative that evades standard QC release tests but creates an immunogenic hapten detectable only by a customized sandwich ELISA with a polyclonal rabbit antibody raised against the hapten-KLH conjugate.

Table 1 – Comparative Activation Efficiency for 4-(Fmoc-amino)-1-methyl-1H-pyrrole-2-carboxylic Acid in Fmoc-SPPS Coupling to a Resin-Bound L-Leucine N-Terminus

Notes: Free amine measured by Kaiser test calibrated against a standard curve at 570 nm. Epimerisation quantified by RP-HPLC of the L/D-Leu diastereomers using a chiral column with 2 mM copper sulfate mobile phase per USP <726>. Data obtained at 22°C with 0.25 mmol scale on ChemMatrix resin, DMF as solvent. Published data for this specific Fmoc monomer is limited; values represent a composite of in-house ranges observed across five independent synthesis campaigns on a Symphony X peptide synthesiser.

Process chemists tasked with scaling a solution-phase peptide fragment condensation using this monomer as the N-terminal component confront a competing beta-elimination pathway that is silent on analytical HPLC until the 10-gram lot is stored at -20°C for 3 weeks and precipitate formation is observed. The alpha-proton at the carbon linking the Fmoc-amino group to the pyrrole ring exhibits a kinetic acidity higher than predicted by simple Hammett correlation, and in solution containing residual triethylamine hydrochloride, a slow elimination of Fmoc-amine occurs yielding a pyrrole-2-carboxylic acid derivative that dimerises. To stabilise the fragment, the free acid is converted to a dicyclohexylamine salt in ethyl acetate and the crystalline salt is stored under nitrogen at 2–8°C; this form maintains a purity of 99.3% over 12 months verified by HPLC at 220 nm. The fragment condensation is then performed in DMF at -15°C using 1.05 equivalents of the salt, HATU, and 2.1 equivalents of 2,4,6-trimethylpyridine to suppress racemisation below the 0.5% detection limit, with the reaction quenched by 0.5 M potassium hydrogen sulfate after 90 minutes. The work-up extraction into MTBE and subsequent solvent switch to acetonitrile must be completed within 5 hours to prevent re-formation of the free acid which is insoluble in organic phases and traps product.

Regulatory Cross-Reference for Multi-Sector Use of a Non-Proteinogenic Fmoc Building Block